Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) gapped down prior to trading on Friday after Cantor Fitzgerald lowered their price target on the stock from $51.00 to $45.00. The stock had previously closed at $26.66, but opened at $25.71. Cantor Fitzgerald currently has an overweight rating on the stock. PTC Therapeutics shares […]
By Sabela Ojea Intel on Thursday delivered a muted outlook for sales in its current quarter. Shares of the chipmaker dropped 10%, to $44.52, in after-hours.
PTC Therapeutics (NASDAQ:PTCT – Get Free Report) had its target price dropped by research analysts at Cantor Fitzgerald from $51.00 to $45.00 in a research note issued on Friday, Benzinga reports. The brokerage currently has an “overweight” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price would indicate a potential upside of 69.43% from […]